Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Gynecologic 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Lymphoma, B-Cell 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mirabegron × Thoracic × Clear all
NCT06534762 2024-08-02

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Zhejiang Provincial People's Hospital

Phase 2 Recruiting
260 enrolled
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡